Shared on 27 Oct 25

Veeva Systems' analyst price target saw a significant increase, rising by more than $80 to reflect higher expectations for sales growth and ongoing customer commitments. Analysts cited the company’s strengthening position in CRM and positive momentum across key pharma relationships.

Shared on 13 Oct 25

Fair value Increased 1.23%

IQVIA Resolution And Embedded AI Will Expand Digital Healthcare Cloud

Narrative Update on Veeva Systems: Analyst Price Target Revision Analysts have raised their fair value estimate for Veeva Systems to approximately $321 per share, up by nearly $4. They cited stronger than expected sales momentum, driven by new major customer commitments and continued growth in key business segments.

Shared on 29 Aug 25

Fair value Increased 5.30%

IQVIA Resolution And Embedded AI Will Expand Digital Healthcare Cloud

Analysts have raised their price target for Veeva Systems to $314.71, citing strong Q2 “beat and raise” results, momentum in both Commercial and R&D segments, successful Vault CRM rollouts with major pharma clients, and ongoing market share gains in life sciences CRM. Analyst Commentary Bullish analysts highlighted Veeva's strong “beat and raise” Q2 results, with both subscription and services revenues growing solidly year-over-year, driven by performance in both Commercial and R&D technology segments.

Shared on 07 May 25

Fair value Increased 12%